Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enigma Dx Secures Additional Funding for Multi-Drug Resistant TB Assay

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
This grant will support further development of Enigma's test for multi-drug resistant tuberculosis on its CE Marked Enigma® Mini Laboratory system.

Enigma Diagnostics has already demonstrated feasibility testing of a single tube assay that can identify and differentiate human and bovine TB in an earlier trial, funded by an initial grant from the Technology Strategy Board’s Biomedical Catalyst programme. The multi-drug resistant tuberculosis (MDR-TB) assay also detects all mutations responsible for Rifampicin and Isoniazid resistance. 

The grant of £1.4m was awarded to a consortium led by Enigma Diagnostics which includes the Clinical TB Research Laboratory, London, headed by Prof. F Drobniewski and Health Sciences Research Ltd. Enigma will focus on further development of the MDR-TB assay and fully automated sample preparation for use on Enigma’s flagship Mini Laboratory (ML) system. 

The Enigma® Mini Laboratory system uniquely combines a number of features critical to PoC testing. The fully automated raw sample to result instrument platform delivers results equivalent to central laboratory standards in up to 70 minutes and can be used by non-technical users in both laboratory and decentralised settings. With this assay, the ML system will be particularly appropriate for use in developing countries and in resource-poor areas where multi-drug resistant tuberculosis is an ever-increasing problem. The ML system’s ease of use requires minimal training and has shown nil operator variance in recent trials, a major issue for other laboratory based diagnostic instruments where testing is undertaken by different operators. Together, these features offer physicians a paradigm shift in their ability to make fully informed treatment decisions and patients fast and accurate diagnosis with immediate treatment. 

John McKinley, Chairman of Enigma Diagnostics, said: “With this grant, The Technology Strategy Board has recognised the importance of supporting Enigma to develop complex diagnostic assays on its ML system which can ultimately save patients’ lives. Our sophisticated multiplexing technology provides unprecedented levels of urgently required diagnostic information to clinicians working in a range of healthcare locations. We recognise MDR-TB as a significant healthcare issue and this grant will enable Enigma to broaden its commercialisation programme to include this important test.” 

Integrated into the Technology Strategy Board’s Stratified Medicine Innovation Platform, the Detection & Identification of infectious agents (DIIA) platform was established in 2008 with the aim of reducing the economic burdened, death and illness due to infectious diseases in humans and animals. Projects supported under the DIIA platform have used public funding to encourage the development and adoption of clinically useful, commercially viable diagnostic solutions. 

Dr Penny Wilson, who manages the programme for the Technology Strategy Board, said: “The development of clinically useful decentralised diagnostic tests for tuberculosis requires the convergence of excellence in a broad spectrum of capabilities and we are delighted to be supporting projects in this area for the benefit of economic growth and public health. We wish Enigma Diagnostics every success in rising to the challenge and look forward to following the company’s progress.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Enigma Diagnostics, ICDC Announce MDx Collaboration
Collaboration aims to develop a rapid and convenient MDx technology for infectious disease pathogens utilising Enigma’s proprietary chemistries and the Enigma® Mini Laboratory system.
Thursday, May 15, 2014
Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory
The worldwide licence covers a broad range of technologies which are important elements of Enigma’s real-time PCR systems.
Friday, August 24, 2007
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos